Colorado Enbrel payment limit set at $600 per unit, impacting Amgen’s pricing strategy and potentially influencing other states.
• Colorado board sets $600 payment limit on Enbrel.
• Limit applies to state health plans and government agencies.
• Decision may influence other states’ drug pricing strategies.
In a groundbreaking move, the Colorado Prescription Drug Affordability Board has voted to set a payment limit on the arthritis medication Enbrel, manufactured by Amgen. This decision marks the first time a state has imposed such a restriction, potentially setting a precedent for other states to follow. The board’s decision establishes an upper payment limit of $600 per unit for Enbrel, aligning with the maximum fair price set to be implemented by Medicare in January. This translates to an annual cost of approximately $30,350 per person, significantly lower than the $53,000 average paid by insurance plans in Colorado in 2023.
The decision is expected to have wide-reaching implications for both Amgen and the broader pharmaceutical industry. By setting this limit, Colorado aims to reduce the financial burden on state health plans and government agencies that provide insurance coverage to residents. The move could encourage other states to adopt similar strategies to control prescription drug spending.
Amgen’s Enbrel is a blockbuster drug widely prescribed for arthritis treatment. The company’s pricing strategy may need to adapt in response to this new regulation. The decision could also impact Amgen’s revenue from Enbrel sales in Colorado, potentially influencing its market strategy in other regions.
The broader market impact of this decision remains to be seen. Analysts suggest that if other states follow Colorado’s lead, it could lead to a significant shift in how drug prices are negotiated and set across the United States. This could also affect the competitive landscape, as pharmaceutical companies may need to adjust their pricing models to remain competitive.
For more insights on market access and pricing strategies, visit our Market Access section.